Valuation: Intra-Cellular Therapies, Inc.

Market Cap 14.02B 12.27B 11.31B 10.48B 19.9B 1,331B 20.22B 136B 52.73B 657B 52.64B 51.5B 2,270B P/E 2023
-49.2x
P/E 2024 -115x
Enterprise Value 13.04B 11.41B 10.51B 9.75B 18.5B 1,237B 18.8B 126B 49.03B 611B 48.95B 47.89B 2,111B EV / Sales 2023
13.8x
EV / Sales 2024 11.6x
Free-Float
95.68%
Yield 2023 *
-
Yield 2024 -
3 years 45.5
Extreme 45.5
131.98
5 years 28.4
Extreme 28.4
131.98
10 years 6.75
Extreme 6.75
131.98
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 2022-03-31
Compliance Officer 64 2019-07-01
Corporate Secretary - -
Date Insider Type Main position Quantity % Market Cap.
25-04-01Issuer sale

Director

55,511 0.0522%
25-04-01Issuer sale

EVP, Chief Commercial Officer

167,824 0.1578%
25-04-01Issuer sale

Director

242,551 0.2281%
Change 5-day change 1-year change 3-year change Capi.($)
-0.04%-.--%-.--%+111.77% 14.02B
+4.07%+8.45%+25.67%-2.34% 66.11B
-0.24%-3.13%+49.38%+223.97% 55.3B
+1.21%+42.20%+42.20%+42.20% 42.44B
-0.55%+7.47%-50.27%-53.80% 41.28B
-2.48%+13.91%+166.79%-32.89% 32.46B
-1.32%-4.79%+58.07%-25.22% 30.78B
+2.10%+4.14%+75.49%+90.19% 23.1B
-0.57%+9.05%+5.15%+186.94% 20.06B
-0.04%+3.85%+67.76%+135.89% 17.19B
Average +0.23%+4.16%+44.02%+67.67% 34.27B
Weighted average by Cap. +0.59%+4.17%+41.89%+57.46%

Financials

2023 2024
Net sales 464M 406M 375M 347M 659M 44.07B 670M 4.49B 1.75B 21.75B 1.74B 1.71B 75.18B 681M 596M 549M 509M 966M 64.62B 982M 6.58B 2.56B 31.89B 2.56B 2.5B 110B
Net income -140M -122M -113M -104M -198M -13.26B -201M -1.35B -525M -6.54B -524M -513M -22.61B -74.68M -65.35M -60.23M -55.82M -106M -7.09B -108M -722M -281M -3.5B -280M -274M -12.09B
Net Debt -481M -421M -388M -360M -683M -45.65B -694M -4.65B -1.81B -22.53B -1.81B -1.77B -77.87B -984M -861M -794M -736M -1.4B -93.4B -1.42B -9.52B -3.7B -46.09B -3.69B -3.61B -159B
Logo Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs that address underserved medical needs primarily in psychiatric and neurological disorders. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Lumateperone is also being studied for the treatment of major depressive disorder, and other psychiatric and neurological disorders. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as the ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program.
Employees
860
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. ITCI Stock